The standard pharmaceutical development path for products that target pathogens moves slowly from studying safety, dosing, and biological responses in hundreds of people to an expensive efficacy trial with thousands of participants at high risk of becoming naturally infected.
Not exact matches
They cite the example of TransCelerate BioPharma, a group of 10 major
pharmaceutical companies that came together to share and direct resources toward selected priorities in order to improve the efficiency of drug
development, such as clinical trial site qualification
standards.
The CIC was founded in 2002 as an international association of
pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and
development with the ultimate goal of making cancer immunotherapies part of the
standard - of - care in oncology.